AGM Details

  • Date: Wednesday, September 23, 2026
  • Time: 03:00 P.M. IST
  • Mode: Video Conferencing (VC) / Other Audio Visual Means (OAVM) as per MCA Circular No. 09/2024 dated September 19, 2024, and SEBI Circulars.
  • Cut-off date for determining members entitled to vote: September 18, 2026
  • Share transfer book closure: September 17, 2026 to September 23, 2026 (both days inclusive)

Business to be Transacted

Ordinary Business

1. Adoption of Financial Statements: To receive, consider, and adopt the audited standalone financial statements for the financial year ended March 31, 2026, together with the reports of the Board of Directors and Auditors.

2. Appointment of Director: To appoint Ms. Chaitali Kalpataru Shah (DIN: 11167778), who retires by rotation and is eligible for re-appointment.

Special Business

3. Change in Designation: To approve the change in designation of Ms. Chaitali Kalpataru Shah from Executive Director to Managing Director with effect from August 25, 2026, for the remainder of her existing tenure until July 28, 2029. The remuneration will be as per terms set out in the explanatory statement and within the limits prescribed under the Companies Act, 2013 and Schedule V.

4. Re-appointment of Director: To appoint Mr. Omprakash Pyarelal Sonar (DIN: 11031877) as Non-Executive Independent Director. He was appointed as an Additional Director effective June 30, 2026.

5. Re-appointment of Director: To appoint Mr. Vivek Mukesh Yadav (DIN: 11033957) as Non-Executive Independent Director. He was appointed as an Additional Director effective June 30, 2026.

6. Appointment of Statutory Auditors: To appoint M/s. Sarang Shivajirao Chavan & Associates, Chartered Accountants (FRN: 159649W), as statutory auditors from the conclusion of the 39th AGM until the conclusion of the 43rd AGM. Their remuneration will be determined by the Board.

7. Increase in Authorized Share Capital: To increase the authorized share capital from ₹20,00,00,000 (Rupees Twenty Crore) divided into 2,00,00,000 equity shares of ₹10 each to ₹70,00,00,000 (Rupees Seventy Crore) divided into 7,00,00,000 equity shares of ₹10 each. Consequently, to alter Clause V of the Memorandum of Association.

8. Re-appointment of Director: To appoint Mr. Mahesh Singh (DIN: 11814569) as Non-Executive Independent Director. He was appointed as an Additional Director effective August 25, 2026.

9. Re-appointment of Director: To appoint Mr. Anil Singh (DIN: 09338444) as Non-Executive Non-Independent Director. He was appointed as an Additional Director effective August 25, 2026.

E-Voting Instructions

The company is providing e-voting facilities through NSDL as per Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI LODR Regulations.

  • Remote e-voting period: September 20, 2026 (9:00 AM IST) to September 22, 2026 (5:00 PM IST)
  • E-voting during AGM: Members who have not cast their vote via remote e-voting can vote during the AGM.
  • Scrutinizer: Ramesh Chandra Bagdi & Associates, Company Secretaries, appointed to scrutinize the voting process.

Other Key Information

  • Company Identification Number (CIN): L24200MH1987PLC043427
  • Email for investor queries: bacilpharma07@gmail.com
  • Share Transfer Agent: Big Share Services Pvt. Ltd., Mumbai
  • Bankers: Union Bank of India, Mumbai
  • Internal Auditor: Sarang Shivajirao Chavan and Associates, Chartered Accountants
  • Secretarial Auditor: M/s. Ramesh Chandra Bagdi & Co., Practicing Company Secretary

Director Details (As per Annexure)

  • Ms. Chaitali Kalpataru Shah (DIN: 11167778): MBA, appointed on July 16, 2025. Holds no shares in the company. Proposed remuneration as Managing Director is within Schedule V limits.
  • Mr. Omprakash Pyarelal Sonar (DIN: 11031877): Graduate, expertise in trading and product sales.
  • Mr. Vivek Mukesh Yadav (DIN: 11033957): Graduate, expertise in finance and accounts.
  • Mr. Mahesh Singh (DIN: 11814569): Graduate, expertise in product sales and business development.
  • Mr. Anil Singh (DIN: 09338444): Graduate, experience in business management and commercial activities.

Financial Impact

  • The increase in authorized share capital has no immediate financial impact but enables future fundraising.
  • The appointment of auditors and directors involves remuneration to be determined by the Board, but no specific amounts are disclosed in the notice.